Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

Mostrar otras versiones (2)

Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The papain-like protease (PLpro) domain of Nsp3 from SARS-CoV-2 is essential for viral replication. In addition, PLpro dysregulates the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanders, Brian C., Pokhrel, Suman, Labbe, Audrey D., Mathews, Irimpan I., Cooper, Connor J., Davidson, Russell B., Phillips, Gwyndalyn, Weiss, Kevin L., Zhang, Qiu, O’Neill, Hugh, Kaur, Manat, Schmidt, Jurgen G., Reichard, Walter, Surendranathan, Surekha, Parvathareddy, Jyothi, Phillips, Lexi, Rainville, Christopher, Sterner, David E., Kumaran, Desigan, Andi, Babak, Babnigg, Gyorgy, Moriarty, Nigel W., Adams, Paul D., Joachimiak, Andrzej, Hurst, Brett L., Kumar, Suresh, Butt, Tauseef R., Jonsson, Colleen B., Ferrins, Lori, Wakatsuki, Soichi, Galanie, Stephanie, Head, Martha S., Parks, Jerry M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044120/
https://www.ncbi.nlm.nih.gov/pubmed/36977673
http://dx.doi.org/10.1038/s41467-023-37254-w

Ejemplares similares

Ejemplares similares